Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Donate Correa, J ^a,b   Dominguez Pimentel V ^a   Mendez Perez M L ^a   Muros De Fuentes, M ^a,b   Mora Fernandez C ^a,b   Martin Nunez E ^a   Cazana Perez V ^a   Navarro Gonzalez J F ^a,b  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b GEENDIAB Grupo Español para el Estudio de la Nefropatía Diabética REDINREN RD12 0021 0019   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; PARATHYROID HORMONE; PARICALCITOL; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR; ANTIINFLAMMATORY AGENT; CALCITRIOL RECEPTOR; ERGOCALCIFEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOMODULATION; MALE; MIDDLE AGED; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CHRONIC KIDNEY FAILURE; INFLAMMATION; METABOLISM; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; ERGOCALCIFEROLS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INFLAMMATION; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROSPECTIVE STUDIES; RECEPTORS, CALCITRIOL; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84893169753     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/670475     Document Type: Article

References (33)

1. Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C.-Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England Journal of Medicine 2004 351 13 1296 1305 2-s2.0-4644221457 10.1056/NEJMoa041031 (Pubitemid 39268908)
2. Navarro-González J. F., Mora-Fernández C., Muros M., Herrera H., García J., Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clinical Journal of the American Society of Nephrology 2009 4 1646 1654 10.2215/CJN.02420409
3. Tentori F., Blayney M. J., Albert J. M., Gillespie B. W., Kerr P. G., Bommer J., Young E. W., Akizawa T., Akiba T., Pisoni R. L., Robinson B. M., Port F. K., Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases 2008 52 3 519 530 2-s2.0-49749113618 10.1053/j.ajkd.2008.03.020
4. Levin A., Bakris G. L., Molitch M., Smulders M., Tian J., Williams L. A., Andress D. L., Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International 2007 71 1 31 38 2-s2.0-33845700085 10.1038/sj.ki.5002009 (Pubitemid 44967731)
5. Joy M. S., Karagiannis P. C., Peyerl F. W., Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. Journal of Managed Care Pharmacy 2007 13 5 397 411 2-s2.0-34547412479 (Pubitemid 47162414)
6. Patel T. V., Singh A. K., Role of vitamin D in chronic kidney disease. Seminars in Nephrology 2009 29 2 113 121 2-s2.0-64049094752 10.1016/j. semnephrol.2009.01.004
7. Dunlay R., Rodriguez M., Felsenfeld A. J., Llach F., Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney International 1989 36 6 1093 1098 2-s2.0-0024797974 (Pubitemid 20049217)
8. Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K. J., Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. Journal of Clinical Investigation 1984 74 6 2136 2143 2-s2.0-0021748474 (Pubitemid 15197358)
9. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J. M., Thadhani R., Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. The New England Journal of Medicine 2003 349 5 446 456 2-s2.0-0042343804 10.1056/NEJMoa022536 (Pubitemid 36910023)
10. Shinaberger C. S., Kopple J. D., Kovesdy C. P., McAllister C. J., van Wyck D., Greenland S., Kalantar-Zadeh K., Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clinical Journal of the American Society of Nephrology 2008 3 6 1769 1776 2-s2.0-58149354524 10.2215/CJN.01760408
11. Russell J., Lettieri D., Sherwood L. M., Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986 119 6 2864 2866 2-s2.0-0023034788 (Pubitemid 17193160)
12. Silver J., Russell J., Sherwood L. M., Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proceedings of the National Academy of Sciences of the United States of America 1985 82 12 4270 4273 2-s2.0-0006519608 (Pubitemid 15053625)
13. Izquierdo M. J., Cavia M., Muñiz P., Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrology 2012 27 13, article 159
14. Piñera-Haces C., Izquierdo-Ortiz M. J., Martín-de Francisco L. Á., Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis. Nefrología 2013 18 33 77 84
15. Navarro-González J. F., Donate-Correa J., Méndez M. L., de Fuentes M. M., García-Pérez J., Mora-Fernández C., Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. The Journal of Clinical Pharmacology 2013 53 421 426
16. Martin K. J., González E. A., Gellens M., Hamm L. L., Abboud H., Lindberg J., 19-nor-1- α -25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Journal of the American Society of Nephrology 1998 9 8 1427 1432 2-s2.0-0345403572 (Pubitemid 28354552)
17. Hervás Sánchez J. G., Prados Garrido M. D., Polo Moyano A., Cerezo Morales S., Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease. Nefrologia 2011 31 6 697 706 2-s2.0-84858318642 10.3265/Nefrologia.pre2011.Aug.11030
18. Hadjiyannakos D., Filipoulos V., Trompouki S., Tretament with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study. Clinical Kidney Journal 2013 6 164 168
19. Andress D., Nonclassical aspects of differential vitamin D receptor activation: Implications for survival in patients with chronic kidney disease. Drugs 2007 67 14 1999 2012 2-s2.0-34948882837 (Pubitemid 47524562)
20. Dusso A. S., Brown A. J., Slatopolsky E., Vitamin D. American Journal of Physiology: Renal Physiology 2005 289 1 F8 F28 2-s2.0-20844431892 10.1152/ajprenal.00336.2004 (Pubitemid 40863568)
21. Lin R., White J. H., The pleiotropic actions of vitamin D. BioEssays 2004 26 1 21 28 2-s2.0-0345743611 10.1002/bies.10368 (Pubitemid 38095345)
22. Sánchez-Niño M. D., Bozic M., Córdoba-Lanus E., Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. American Journal of Physiology: Renal Physiology 2011 302 647 657
23. Tan X., Wen X., Liu Y., Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF- B signaling. Journal of the American Society of Nephrology 2008 19 9 1741 1752 2-s2.0-54749105918 10.1681/ASN.2007060666
24. Kim C. S., Joo S. Y., Lee K. E., Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inflammation and epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. PLoS ONE 2013 17 8 e63186
25. Alborzi P., Patel N. A., Peterson C., Bills J. E., Bekele D. M., Bunaye Z., Light R. P., Agarwal R., Paricalcitol reduces albuminuria and inflammation in chronic kidney disease a randomized double-blind pilot trial. Hypertension 2008 52 2 249 255 2-s2.0-49849104171 10.1161/HYPERTENSIONAHA.108.113159
26. Eleftheriadis T., Antoniadi G., Liakopoulos V., Kartsios C., Stefanidis I., Galaktidou G., Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF- α and IL-8 production by human peripheral blood mononuclear cells. International Urology and Nephrology 2010 42 1 181 185 2-s2.0-77950916486 10.1007/s11255-009-9541-1
27. Zoccali C., Tripepi G., Mallamaci F., Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? Journal of the American Society of Nephrology 2006 17 3 S169 S173 2-s2.0-33845268461 10.1681/ASN.2006080910 (Pubitemid 44865244)
28. Kessler M., Zannad F., Lehert P., Grünfeld J. P., Thuilliez C., Leizorovicz A., Lechat P., Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study. Nephrology Dialysis Transplantation 2007 22 12 3573 3579 2-s2.0-36749072988 10.1093/ndt/gfm417 (Pubitemid 350212486)
29. Parekh R. S., Plantinga L. C., Kao W. H. L., Meoni L. A., Jaar B. G., Fink N. E., Powe N. R., Coresh J., Klag M. J., The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney International 2008 74 10 1335 1342 2-s2.0-55249101446 10.1038/ki.2008.449
30. Ramirez R., Carracedo J., Berdud I., Carretero D., Merino A., Rodríguez M., Tetta C., Martín-Malo A., Aljama P., Microinflammation in hemodialysis is related to a preactivated subset of monocytes. Hemodialysis International 2006 10 1 S24 S27 2-s2.0-33144478326 10.1111/j.1542-4758.2006.01186.x (Pubitemid 43263304)
31. Kostulas N., Pelidou S. H., Kivisäkk P., Kostulas V., Link H., Increased IL-1 β IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 1999 30 10 2174 2179 2-s2.0-0032589394 (Pubitemid 29473266)
32. Akatsu T., Nakamura M., Satoh M., Hiramori K., Increased mRNA expression of tumour necrosis factor- α and its converting enzyme in circulating leucocytes of patients with acute myocardial infarction. Clinical Science 2003 105 1 39 44 2-s2.0-0038004794 10.1042/CS20020367 (Pubitemid 36819574)
33. Dobrez D. G., Mathes A., Amdahl M., Marx S. E., Melnick J. Z., Sprague S. M., Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrology Dialysis Transplantation 2004 19 5 1174 1181 2-s2.0-2442587499 10.1093/ndt/gfh123 (Pubitemid 38628138)